Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer

作者：Quenel Tueux Nathalie^*; Debled Marc; Rudewicz Justine; MacGrogan Gaetan; Pulido Marina; Mauriac Louis; Dalenc Florence; Bachelot Thomas; Lortal Barbara; Breton Callu Christelle; Madranges Nicolas; de lara Christine Tunon; Fournier Marion; Bonnefoi Herve; Soueidan Hayssam; Nikolski Macha; Gros Audrey; Daly Catherine; Wood Henry; Rabbitts Pamela; Iggo Richard

来源：British Journal of Cancer, 2015, 113(4): 585-594.

DOI：10.1038/bjc.2015.247

• anastrozole
• endocrine treatment
• fulvestrant
• hormone-receptor-positive cancer
• large operable or locally advanced breast cancer
• neo-adjuvant

Background: The aim of this study was to assess the efficacy of neoadjuvant anastrozole and fulvestrant treatment of large operable or locally advanced hormone-receptor-positive breast cancer not eligible for initial breast-conserving surgery, and to identify genomic changes occurring after treatment.
Methods: One hundred and twenty post-menopausal patients were randomised to receive 1mg anastrozole (61 patients) or 500mg fulvestrant (59 patients) for 6 months. Genomic DNA copy number profiles were generated for a subgroup of 20 patients before and after treatment.
Results: A total of 108 patients were evaluable for efficacy and 118 for toxicity. The objective response rate determined by clinical palpation was 58.9% (95% CI = 45.0-71.9) in the anastrozole arm and 53.8% (95% CI = 39.5-67.8) in the fulvestrant arm. The breast-conserving surgery rate was 58.9% (95% CI = 45.0-71.9) in the anastrozole arm and 50.0% (95% CI = 35.8-64.2) in the fulvestrant arm. Pathological responses >50% occurred in 24 patients (42.9%) in the anastrozole arm and 13 (25.0%) in the fulvestrant arm. The Ki-67 score fell after treatment but there was no significant difference between the reduction in the two arms (anastrozole 16.7% (95% CI = 13.3-21.0) before, 3.2% (95% CI = 1.9-5.5) after, n = 43; fulvestrant 17.1% (95% CI = 13.1-22.5) before, 3.2% (95% CI = 1.8-5.7) after, n = 38) or between the reduction in Ki-67 in clinical responders and non-responders. Genomic analysis appeared to show a reduction of clonal diversity following treatment with selection of some clones with simpler copy number profiles.
Conclusions: Both anastrozole and fulvestrant were effective and well-tolerated, enabling breast-conserving surgery in over 50% of patients. Clonal changes consistent with clonal selection by the treatment were seen in a subgroup of patients.

• 出版日期2015-8-11